마크로젠 로고

As the $1,000 genome has been realized, human society is rapidly advancing
into the era of precision medicine that is capable of predicting, diagnosing,
and treating diseases based on big data that integrates medical and
genomic information. Recognizing the importance of genomic medicine as a key to
innovative change in the medical paradigm and the realization of precision medicine,
we have made outstanding progress in research in the field of genomic analysis.
Particularly, we became the fourth company in the world to analyze the entire
genome of Koreans with the individual genome analysis results in 2009 and
the first when it comes to Northern Asian genome analysis results. In 2016,
we managed to overcome the limitations of the existing international standard
genome and achieve the world's most complete Asian standard genome
applicable to future precision medicine.

Macrogen has constantly evolved and adapted to the changing market for
the last two decades and is prepared to become the global No. 1 company
in the "Genome Foundry" industry by expanding its domestic and international
genome centers' operations based on the new management structure and
the mid-to-long term vision called "Macrogen 2.0." Macrogen is currently striving
to take another leap in the clinic business by providing health check-up services
tailored to each person's genes for disease predictions at its medical institutions,
including Macrogen Medical Foundation's Gene Health Check-up Center.
While vertically integrating our business areas including the upstream and
downstream businesses related to DNA analysis, Macrogen, a healthcare company
with a pivot on "wellness," will continue to expand our global network. Furthermore,
Macrogen will continue making progress toward the goal of empowering humans to
achieve longevity without diseases by tapping into the digital transformation in
healthcare empowered by the convergence of big data, including genomic data,
and AI-driven analysis technologies.